P/B
6,1
Roivant Sciences
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
$25.9B
Market Cap • 9/25/2026
2014
(12 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United Kingdom
Country
Valuation
P/S
3433,2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
5,8
EPS
—
Market Cap
Market Cap
25,9B
EV
22,8B
EV/Revenue
3029,1
EV/EBITDA
-38,5
EV/EBIT
-38,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0,4%
Total Yield
0,4%
Payout
0%
Retained Earnings
-900,4M
Profitability
Gross Margin
81,2%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
9704,1%
Capex/Revenue
61%
Capex/D&A
161,2%
Capex/OCF
-0,6%
SBC/OCF
—
% PPE
1,7%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-27,9%
CAGR Op. Income 5Y
-18,3%
CAGR Net Income 5Y
-20,8%
CAGR EPS 5Y
-17,7%
CAGR OCF 5Y
7%
Leverage
N.D./EBITDA
6,3
Debt/Equity
0%
Current Ratio
16,7
Quick Ratio
16,3
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!